Video

Dr. Costello on Tailoring Induction Therapy for Standard- and High-Risk Multiple Myeloma

Caitlin Costello, MD, discusses tailoring induction therapy for patients with standard-risk and high-risk multiple myeloma.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Caitlin Costello, MD, hematologist/medical oncologist, assistant professor of medicine, University of California, San Diego ​Health, discusses tailoring induction therapy for patients with standard-risk and high-risk multiple myeloma.

    The goal of induction therapy across risk subgroups is to eliminate as much cancer as possible, Costello says. Ideally, the patient will achieve a complete remission (CR) or stringent CR. 

    However, optimizing treatment for patients based on risk remains a challenge, explains Costello.

    It appears that patients with high-risk multiple myeloma who have highly proliferative and aggressive disease require a more aggressive induction regimen, Costello says.

    Several ongoing clinical trials are investigating how to best tailor therapy to patients with standard- vs high-risk disease, concludes Costello.